AKE 0.00% $9.83 allkem limited

Scoping studies for phase II "due back end of september"...

  1. 1,340 Posts.
    lightbulb Created with Sketch. 29
    Scoping studies for phase II "due back end of september" (According to CEO Richard Seville).

    OrocobreExpansion.PNG
    Once the market gets reminded of the growth potential of this company and is given a clear vision and plan we will see the SP back on an upward trajectory.
 
watchlist Created with Sketch. Add AKE (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.